Metropolis Healthcare Ltd Share Price

Overview

Metropolis Healthcare Ltd share price is currently ₹567.76, up by ₹2.21 (0.39%) from its previous closing price of ₹565.55. The share price has declined -3.18% over the past month and gained 5.82% over the past year. The stock's 52-week low and high are ₹407.56 and ₹601.60, respectively. Metropolis Healthcare Ltd has a market capitalisation of ₹ 11,550.00 Cr. The share price was last updated on 27 Aug 2026, 03:30 PM IST.

Metropolis Healthcare Ltd
Metropolis Healthcare Ltd
METROPOLIS
 0.00
 2.21
0.39%
Healthcare
 0.00(%)1D

Updated: 27 Aug 2026, 03:30:02 pm IST

Market Data

Open Price

 565.13

Prev. Close

 565.55
 559.34

Day Low

 570.49

Day High

 407.56

52 Week Low

 601.60

52 Week High

HealthcareHospital & Healthcare Services
CategoryMid Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

58.35

Sector PE

42.03

PB Ratio

7.84

Sector PB

5.82

EPS

9.73

Dividend Yield

1.15

Today's Volume

295.327 K

5 Day Avg. Volume

255.473 K

PEG Ratio

-0.87

Market Cap.

₹ 11,550.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsInterim Dividend of 50% at ₹1/Share
19-May-202619-May-2026
Bonus3:1
20-Mar-202620-Mar-2026
DividendsInterim Dividend of 200% at ₹4/Share
11-Nov-202511-Nov-2025

Mutual Fund Ownership

Mutual Fund Holder
Jun 26
Shares held
Jul 26
Shares held
HDFC Focused Fund - Regular Plan - Growth68.00 Lac
68.00 Lac
no change
HDFC Flexi Cap Fund - Growth65.00 Lac
65.00 Lac
no change
Kotak Small Cap Fund - Growth63.80 Lac
63.80 Lac
no change
Nippon India Small Cap Fund - Growth45.81 Lac
45.81 Lac
no change
Franklin India Small Cap Fund - Growth43.73 Lac
43.73 Lac
no change

About Metropolis Healthcare Ltd 👋

Metropolis Healthcare Limited is engaged in providing diagnostic services to patients, healthcare providers, and corporates across India and Africa. It has a single operating segment, namely Pathology services. It is engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, other pathological and radiological investigations. Its services include Pathology Testing Services, Corporate Wellness, Lab In Hospitals and Clinical Research Services. It serves a diverse customer base, including B2C (Business to Consumer), B2B (Business to Business), and institutional clients. It offers more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. Its footprint spans 28 states, seven Union Territories.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Dhwani Patel

Dhwani Patel

23 Aug • 9:08 AM · SEBI-Registered Analyst

Metropolis Healthcare Shows Stronger Earnings Momentum

METROPOLIS
is showing a meaningful improvement in its fundamental trajectory, supported by stronger revenue growth, better operating leverage and healthy profitability across its diagnostics business. The latest Q1 FY27 numbers also continued the growth trend, with consolidated revenue rising to roughly ₹455 crore and net profit reaching nearly ₹57 crore. Overall, the combination of higher testing volumes, specialty diagnostics, expanding reach and improving margins provides a constructive fundamental backdrop for the stock. On the technical front, Metropolis Healthcare is developing a well-defined ascending triangle on the daily chart, a structure that generally reflects a gradual shift in control towards buyers. The stock has repeatedly approached the ₹580–₹595 region, creating a relatively flat resistance zone, while the successive higher lows form a clearly rising support trendline. This combination suggests that sellers are finding it increasingly difficult to push the price back to previous lows, while buyers continue to absorb supply on declines. The recent move towards the upper boundary, accompanied by a strong daily advance, keeps the setup constructive and raises the probability of a breakout attempt. A sustained close above ₹595 would provide confirmation of the pattern and could open the way towards the ₹640–₹660 zone, subject to momentum and volume confirmation. On the downside, ₹535–₹540 remains an important immediate support area, while the rising trendline around the ₹450–₹460 region represents the broader structural support.

See More
Shashank Gupta

Shashank Gupta

12 Aug • 8:40 AM · SEBI-Registered Analyst

Metropolis Healthcare Promoters Offload ₹118 Crore Stake

METROPOLIS
: On August 11, 2026, promoter entities of Metropolis Healthcare Ltd., namely Duru Shah Family Trust and Metz Advisory LLP, sold a combined 21 lakh shares (1.01% stake) at ₹564 per share, amounting to ₹118.44 crore. The transaction saw strong institutional participation, with Aditya Birla Sun Life Mutual Fund acquiring 10.49 lakh shares, while ICICI Prudential Mutual Fund and Morgan Stanley Asia Singapore Pte each bought 5.25 lakh shares. This move slightly reduces promoter holding but strengthens institutional ownership, which could enhance long-term stability and governance.

See More
Jeet B Bhayani (SEBI RA)

Jeet B Bhayani (SEBI RA)

7 Aug • 5:38 PM · SEBI-Registered Analyst

Odisha Signs 10 MoUs to Overhaul Healthcare Infrastructure and Services

To strengthen public healthcare, the Government of Odisha has signed 10 Memorandums of Understanding (MoUs) with key institutions to upgrade trauma care, medical education, diagnostics, and infrastructure. Key initiatives include partnering with the All India Institute of Ayurveda to integrate traditional AYUSH practices into trauma care, collaborating with the Adani Group to build rest houses for patients' families, and modernizing district and sub-divisional laboratories. According to Health Minister Mukesh Mahaling, these strategic partnerships align with state and national leadership goals to create a modern, inclusive healthcare ecosystem. By boosting institutional capacity, expanding training, and improving diagnostic access, the state aims to significantly enhance patient outcomes and deliver higher-quality healthcare services statewide.

ADANIENT
TATASTEEL
LALPATHLAB
METROPOLIS

See More
InvestAce Capital

InvestAce Capital

7 Aug • 1:36 PM · SEBI-Registered Analyst

Every Growing Economy Needs Someone to Verify It.

Growth creates transactions. Transactions create the need for trust. Whether it's a medical test, a credit rating, a product certification, an ESG audit or a financial statement, verification becomes more valuable as the economy scales. That's why businesses built around independent validation often enjoy long growth runways.

CRISIL
verifies credit risk.
VIMTALABS
validates products through testing.
METROPOLIS
and !Dr Lal PathLabs verify health through diagnostics. TÜV SÜD India (unlisted) and global certification firms play a similar role in industrial compliance. The bigger an economy becomes, the more important verification becomes. Trust isn't just an outcome of growth. It's an industry in itself.

See More
InvestAce Capital

InvestAce Capital

7 Aug • 9:47 AM · SEBI-Registered Analyst

India's Time Economy Is Getting Bigger.

Ten years ago, Indians mostly spent money on products. Today, they're increasingly spending to save time. Food delivery instead of cooking. Online investing instead of visiting a branch. Air travel instead of trains for business trips. Premium diagnostics with home sample collection instead of waiting at hospitals. This shift is creating opportunities for businesses that monetize convenience rather than consumption.

INDIGO
,
ETERNAL
(Zomato),
SWIGGY
, !Dr Lal PathLabs,
METROPOLIS
,
DREAMFOLKS
and
RATEGAIN
are all beneficiaries of India's growing "time economy." As incomes rise, time often becomes more valuable than money. The businesses that save time may quietly become some of the biggest long-term compounders.

See More
Lovelesh Sharma

Lovelesh Sharma

19 Jul • 9:52 AM · SEBI-Registered Analyst

METROPOLIS
Underperform but Breakout.

HEG Ltd. The stock has been trading in a well-defined range for several months, with support near ₹470. A decisive breakout above ₹620–625 could open the path toward ₹690, while failure to sustain may keep the stock oscillating within the current range.

METROPOLIS

See More

News & Events

Frequently Asked Questions

What is the share price of Metropolis Healthcare Ltd?

What is the market cap of Metropolis Healthcare Ltd?

Should I buy Metropolis Healthcare Ltd stock now?

What is the 52 week high and low of Metropolis Healthcare Ltd?

Is the Metropolis Healthcare Ltd stock good to buy?

Is Metropolis Healthcare Ltd a good buy for the long term?

Is Metropolis Healthcare Ltd overvalued or undervalued?

What is the PE and PB ratio of Metropolis Healthcare Ltd?

Start Now